Abionyx Looks To Next Steps As Renal Sepsis Candidate Succeeds At Phase IIa
Seeking Partnerships And Fundraising
Executive Summary
The French firm’s lead asset has impressed in a Phase IIa trial in sepsis patients at risk of kidney injury, triggering discussions with regulators for a path forward in the challenging and life-threatening condition.